// App-Quantinova.ai

: Clinical and economic outcomes in low-risk pulmonary embolism patients treated with rivaroxaban vs standard of care

Researchers

Presenter

  • W.F. Peacock

Principal Investigators

  • C. Coleman

  • P. Wells

  • G.J. Fermann

  • L. Wang

  • O. Baser

  • J. Schein

  • C. Crivera

Medical Centers

  • Baylor College of Medicine, Emergency Medicine, Houston, United States of America

  • University of Connecticut, School of Pharmacy, Hartford, United States of America

  • University of Ottawa, Department of Medicine, Ottawa, Canada

  • University of Cincinnati, Internal Medicine, Cincinnati, United States of America

  • STATinMED Research, Ann Arbor, MI, United States of America

  • Columbia University, Center for Innovation & Outcomes Research, Surgery Department, New York, United States of America

  • Janssen Scientific Affairs, LLC, Raritan, United States of America

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • N/A

Biomarkers

  • Folate Hydrolase 1

Drug/Treatment

  • Heparin

  • rivaroxaban

  • Warfarin

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Janssen Scientific Affairs

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved